Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss of $1.13/sh

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($1.13), versus $1.31 reported last year. Revenue for the quarter came in at $105 thousand, versus $214 thousand reported last year.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Schwab's May activity shows margin loans nearly double
• Nvidia pitches Vera CPU to Chinese clients with August delivery target